XXXX prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.

@entity1033 @entity10921 @entity1 @entity33 @entity1398 @entity6933
HSV can cause oral lesions that exacerbate chemotherapy-related @entity33 . Intravenous @entity1033 is effective in preventing HSV reactivations, but expensive. @entity6933 has good bioavailability and has not been studied for prophylaxis of HSV among @entity10921 @entity1 . We compared the efficacy and costs of @entity6933 in preventing HSV reactivation among HSV seropositive autologous progenitor cell transplantation (APCT) @entity1 with historical controls in whom intravenous @entity1033 or no HSV prophylaxis were used. @entity6933 group: From October 1997 to April 1999 108 adult @entity1 received @entity6933 500 mg twice daily from day -3 of APCT until @entity1398 recovery or day +30. @entity6933 was switched to intravenous @entity1033 in cases of oral intolerance (17 @entity1 ) or suspected HSV reactivation (five @entity1 ). Intravenous @entity1033 group: From January 1996 to October 1997 43 @entity1 received 5 mg/kg twice-daily intravenous @entity1033 from day -3 until recovery from @entity1398 . No prophylaxis group: 38 @entity1 from January 1996 to October 1997 did not receive HSV prophylaxis. HSV reactivations were seen in 2.7%, 2% and 45% of @entity1 in the @entity6933 , intravenous @entity1033 , and no prophylaxis groups, respectively. @entity6933 was well tolerated and was the least expensive strategy. Oral @entity6933 was as effective as intravenous @entity1033 for the prophylaxis of HSV reactivation in APCT @entity1 .
